The Role of κ Opioid Receptor in Brain Ischemia

Chunhua Chen1, Chunhua Xi, Xuan Liang

  • 11Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.2Department of Anesthesiology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.3Department of Anesthesiology, Renji Hospital, Jiaotong University School of Medicine, Shanghai, China.4Department of Biology, University of Pennsylvania, Philadelphia, PA.

Critical Care Medicine
|August 7, 2016
PubMed
Abstract

Insights

Highly selective kappa opioid receptor agonists, like salvinorin A, show neuroprotective effects in mouse models of brain ischemia. Activation of these receptors reduces infarct volume, improves neurological deficits, and inhibits apoptosis and inflammation.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Ischemic Stroke Research

Background:

  • Previous studies suggest kappa opioid receptor agonists possess neuroprotective properties.
  • Brain ischemia involves complex pathological processes including apoptosis and inflammation.

Purpose of the Study:

  • To investigate the role and mechanisms of kappa opioid receptor agonists in a mouse model of middle cerebral artery occlusion (MCAO).
  • To evaluate the neuroprotective effects of salvinorin A, a selective kappa opioid receptor agonist, in MCAO mice.

Main Methods:

  • Establishment of a middle cerebral artery occlusion (MCAO) model in adult male mice with 120 minutes of ischemia and 24-hour reperfusion.
  • Intranasal administration of varying doses of salvinorin A post-reperfusion; administration of norbinaltorphimine (kappa opioid receptor antagonist) to assess specificity.
  • Assessment of infarct volume, kappa opioid receptor expression, blood-brain barrier integrity (Evans blue extravasation), neurobehavioral outcomes, and levels of apoptosis (caspase-3) and inflammation (IL-10, TNF-α).

Main Results:

  • Kappa opioid receptor expression was significantly upregulated in the ischemic penumbra.
  • Salvinorin A demonstrated a dose-dependent reduction in infarct volume and improvement in neurological deficits.
  • Salvinorin A (50 μg/kg) reduced blood-brain barrier permeability, decreased cleaved caspase-3, IL-10, and TNF-α levels.
  • The effects of salvinorin A were significantly attenuated by the kappa opioid receptor antagonist, norbinaltorphimine.

Conclusions:

  • Kappa opioid receptors are upregulated and play a critical role in brain ischemia-reperfusion injury.
  • Activation of kappa opioid receptors offers potential neuroprotection by preserving the blood-brain barrier, reducing apoptosis, and inhibiting inflammation.
  • Salvinorin A represents a promising therapeutic agent for mitigating brain ischemia-reperfusion damage.